Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Arthritis Res Ther. 2006;8 Suppl 2:S4. Epub 2006 Jul 28.

Interleukin-6 and rheumatic diseases.

Author information

  • Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Rockville Pike, Bethesda, Maryland, USA. lipskyp@mail.nih.gov

Abstract

IL-6 is a pleiotropic cytokine involved in both the initiation and the maintenance of the inflammatory and immunologic responses in certain autoimmune diseases. Blocking of these two complementary functions of IL-6 may confer additive, or even unique, benefits to the patient. The levels of both IL-6 and its soluble receptor (sIL-6Ralpha) are elevated to various degrees in many rheumatic diseases. IL-6 blockade has been shown to be beneficial both in experimental models and in human disease, and inhibition of IL-6 signaling with a molecule such as tocilizumab could prevent or reverse some of the complications typically associated with rheumatic diseases.

PMID:
16899108
[PubMed - indexed for MEDLINE]
PMCID:
PMC2946778
Free PMC Article

Images from this publication.See all images (2)Free text

Figure 1
Figure 2
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Write to the Help Desk